-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Abivax (ABVX), 'ABVX remains our Best Idea'
-
-
-
-
-
-
-
Wedbush Upgrades Abivax (ABVX) to Neutral
-
-
-
-
-
-
-
Abivax files annual reports with French and US regulators
-
-
-
-
-
-
-
Wedbush Starts Abivax (ABVX) at Underperform
-
-
-
-
-
-
-
Leerink Partners on Abivax (ABVX): 'Key Clinical & Regulatory Catalysts on Track'
-
-
-
-
-
-
-
Abivax (ABVX) PT Raised to $150 at Guggenheim, named 'Best Idea'
-
-
-
-
-
-
-
Guggenheim on Abivax (ABVX): 'We expect ABVX to get a late-breaker and/or a plenary session at the UEGW'
-
433,251 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

